{"entity":{"id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","aka":[],"tldr":"A phase 3 trial of Bacillus Calmette-Guerin: Strain Russian BCG-I in bladder & urothelial cancer, run by Verity Pharmaceuticals Inc., now recruiting.","summary":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) is a phase 3 interventional study registered as NCT05037279 by Verity Pharmaceuticals Inc., with 540 participants planned, started 2024-04-24 and due to reach its primary completion in 2029-02. Interventions recorded: Bacillus Calmette-Guerin: Strain Russian BCG-I and Bacillus Calmette-Guerin: Strain TICE.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05037279","url":"https://clinicaltrials.gov/study/NCT05037279"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["verity-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05037279","phase":"3","setting":"A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.","sponsor":"Verity Pharmaceuticals Inc.","enrolled":540,"outcomes":[]},"route":"/trials/nct05037279/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/"}]}}